Plain-English translation of NCT06986174 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a medication called for people with Waldenström macroglobulinemia—a rare blood cancer—whose disease has stopped responding to at least two previous treatments. works by blocking proteins that help cancer cells survive and grow. The medication has been approved by the FDA for a different blood disorder, but this study will test whether it works safely and effectively for this particular cancer.
People with this type of blood cancer often run out of treatment options after their cancer stops responding to standard therapies. This trial is exploring whether this medication might offer a new hope for patients in that situation.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly to take the medication twice daily by mouth for up to 4 years. During your visits, you'll have blood tests, urine tests, heart monitoring tests (ECGs), CT scans, X-rays, and bone marrow biopsies to check how you're responding. After you finish treatment, you'll continue to be followed for 2 years to monitor your health. In total, the active treatment phase lasts up to 4 years, with detailed monitoring throughout and for 2 years afterward.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States